Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

RFS Pharma and Genoscience to Jointly Work on Protease Inhibitors for Viral Infections

  • RFS Pharma and Genoscience Pharma formed a drug discovery joint venture to develop protease inhibitors for the treatment of life-threatening viral infections.

    The companies will collaborate on the discovery, optimization, and development of lead compounds into therapeutic agents. Genoscience’s molecular modeling capabilities will be coupled with RFS Pharma’s expertise in pharmacology and drug development.

    "This strategic alliance expands the breath of our company beyond our expertise in nucleoside analogs," explains Raymond F. Schinazi, founder and executive director of RFS Pharma. “Genoscience also provides RFS Pharma with a presence in Europe for further expansion.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »